Amicus Therapeutics, Inc. $FOLD Stock Holdings Increased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 19.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 223,800 shares of the biopharmaceutical company’s stock after buying an additional 35,903 shares during the quarter. Jefferies Financial Group Inc. owned about 0.07% of Amicus Therapeutics worth $1,282,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of FOLD. Invesco Ltd. raised its position in shares of Amicus Therapeutics by 4.1% during the 1st quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock valued at $21,717,000 after acquiring an additional 105,856 shares in the last quarter. Capital Fund Management S.A. lifted its position in shares of Amicus Therapeutics by 408.8% in the 1st quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock worth $2,550,000 after buying an additional 251,134 shares during the last quarter. Jump Financial LLC boosted its holdings in shares of Amicus Therapeutics by 101.8% in the 1st quarter. Jump Financial LLC now owns 406,168 shares of the biopharmaceutical company’s stock valued at $3,314,000 after buying an additional 204,941 shares during the period. Deutsche Bank AG grew its position in shares of Amicus Therapeutics by 26.4% during the 1st quarter. Deutsche Bank AG now owns 1,038,990 shares of the biopharmaceutical company’s stock valued at $8,478,000 after buying an additional 216,882 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in Amicus Therapeutics during the first quarter worth about $317,000.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on FOLD shares. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. The Goldman Sachs Group increased their target price on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Finally, Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $10.02 on Thursday. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $10.57. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -83.49 and a beta of 0.66. The business has a 50 day simple moving average of $8.73 and a 200 day simple moving average of $7.34.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The firm had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. During the same quarter in the previous year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Insider Activity at Amicus Therapeutics

In other news, insider Ellen Rosenberg sold 23,621 shares of the company’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $10.00, for a total value of $236,210.00. Following the completion of the sale, the insider directly owned 507,710 shares of the company’s stock, valued at approximately $5,077,100. This represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Michael Clark sold 25,643 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $10.10, for a total transaction of $258,994.30. Following the completion of the transaction, the insider owned 296,975 shares of the company’s stock, valued at $2,999,447.50. This trade represents a 7.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 201,652 shares of company stock worth $2,019,288. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.